Business
Notice of Capital Markets Day
Creo Medical Group plc will host a Capital Markets Day for investors and analysts on Wednesday, November 19, 2025, starting at 2:30pm GMT in London. Interested parties can register by contacting Walbrook PR at 020 7933 8780 or via email. This event follows a prior announcement made on October 7, 2025. Disclaimer*
About this update from Creo Medical Group Plc
[{"type":"text","content":"\n\nCreo Medical Group plc\n(\"Creo\", the \"Company\" or the \"Group\")\n \nNotice of Capital Markets Day\n \nCreo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that, further to the announcement on 7 October 2025, the Company will be hosting a Capital Markets Day for investors and analysts from 2:30pm GMT on Wednesday 19 November 2025 in the City of London.\n \nTo register your interest, please contact Walbrook PR on 020 7933 8780 or [email protected].\n \nFor further information please contact: \n \n\n\n\n\nCreo Medical Group plc\n\n\nwww.creomedical.com\n\n\n\n\nRichard Craven, Company Secretary\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n\n\n\n\n\nDeutsche Numis (Nominated Adviser, Broker and Financial Adviser)\nFreddie Barnfield / Duncan Monteith / Sher Shah\n\n\n+44 (0)20 7260 1000\n\n\n\n\n \n\n\n\n\n\n\n\nWalbrook PR Ltd\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Alice Woodings\n \n\n\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\n\n\n\n\n\n\n\n\n\n \n\n \nAbout Creo Medical\nCreo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.\n \nThe Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency (\"RF\") energy for precise localised cutting and focused high frequency microwave (\"MW\") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to pro...